We at Amberen, pride ourselves in the 45 years of scientific research on our primary ingredients and passionately believe in helping all women going through menopause. The scientific foundation that supports Amberen's effectiveness and safety is substantial, which includes multiple clinical studies on menopausal women. Since 2007, it's been our mission to make every woman's transition as symptom-free as possible.
Amberen has been proven in clinical studies including a published 12-week randomized, placebo-controlled, double-blind study on women, between 42-60 years of age with mild to moderate menopause symptoms, that showed Amberen to be an effective, safe and well tolerated supplement.* The below percentages are the clinically shown results from the most recent study.∞
had reduced hot flashes∞
had reduced stress∞
had reduced night sweats∞
had more sex drive∞
had reduced mood swings∞
had reduced headaches∞
had less difficulty sleeping∞
had reduced muscle & joint pain∞
had reduced irritability∞
had less excitability∞
had more energy∞
had less difficulty
concentrating∞
had less difficulty
sleeping∞
had reducedmuscle &
joint pain∞
had reduced irritability∞
had less excitability∞
had more energy∞
had less difficulty
concentrating∞
Amberen’s perimenopause formula has been clinically tested on 105 perimenopausal women between the ages of 36-50 with mild to moderate symptoms. The results of this 6-month double-blind, randomized, and placebo-controlled study show that our new formula is an effective, safe and well-tolerated supplement for perimenopause.* In fact, 74% of perimenopausal women experienced menstrual regularity^ and relief from the following symptoms:
had reduced hot flashes∞
had reduced anxiety and stress∞
had reduced night sweats∞
had less fatique∞
had reduced mood swings∞
had more sex drive∞
had less difficulty sleeping∞
had reduced headaches∞
had reduced irritability∞
had reduced muscle & joint pain∞
had less difficulty sleeping∞
had reduced headaches∞
had reduced irritability∞
had reduced muscle & joint pain∞
Amberen has been proven in clinical studies including a published 12-week randomized, placebo-controlled, double-blind study on women, between 42-60 years of age with mild to moderate menopause symptoms, that showed Amberen to be an effective, safe and well tolerated supplement.* The below percentages are the clinically shown results from the most recent study.∞
had reduced hot flashes∞
had reduced stress∞
had reduced night sweats∞
had more sex drive∞
had reduced mood swings∞
had reduced headaches∞
had less difficulty sleeping∞
had reduced muscle & joint pain∞
had reduced irritability∞
had less excitability∞
had more energy∞
had less difficulty
concentrating∞
had less difficulty
sleeping∞
had reducedmuscle &
joint pain∞
had reduced irritability∞
had less excitability∞
had more energy∞
had less difficulty
concentrating∞
had reduced hot flashes∞
had reduced anxiety and stress∞
had reduced night sweats∞
had less fatique∞
had reduced mood swings∞
had more sex drive∞
had less difficulty sleeping∞
had reduced headaches∞
had reduced irritability∞
had reduced muscle & joint pain∞
had less difficulty sleeping∞
had reduced headaches∞
had reduced irritability∞
had reduced muscle & joint pain∞
Today’s Amberen formulation is the result of decades of sophisticated, rigorous testing, and scientific discoveries. Click below to learn more about our clinical studies and the scientific achievements from the last 45 years of research on the Amberen formulation and its main ingredients.
1971
Scientific Research
Small doses of amber (succinic) acid were used to rejuvenate the hypothalamus by restoring its sensitivity.
V.M. Dilman, V.N. Anisimon, and M.N. Kondrashova. The influence of succinic (amber) and glutamic acids on the sensitivity of hypothalamo-gonadotropic system to inhibitory action of estrogens in old rats. Pharmacology and Toxicology 3, 540-551, 1976 (In Rus).
1978
Scientific Research
In pre-clinical trials, succinic acid showed to improve menopausal changes and also exhibited very distinct signs of rejuvenation.
V.M. Dilman and V. N. Anisimov. Hypothalamic mechanisms of ageing and of specific age pathology—I. Sensitivity threshold of hypothalamo-pituitary complex to homeostatic stimuli in the reproductive system. Experimental gerontology 14.4 (1979): 161-173.
1999
Scientific Research
Enerlit-Clima (equivalent of Amberen’s formulation) composition was developed. In preclinical trials, the supplement was shown to be safe (no acute or long-term toxicity) and to be effective for the alleviation of more than 12 menopausal symptoms.
2001
Clinical Trial
Evaluation of Enerlit-Clima (equivalent of Amberen’s formulation) as a treatment for climacteric syndrome.
Study design: This randomized, placebo-controlled, double-blind, 3-week study involved 70 menopausal women.
Results: The results of the study demonstrated that Enerlit-Clima-based therapy helps alleviate many menopause symptoms when compared with the placebo group. No adverse side effects when taking Enerlit-Clima were registered.
Publication: E.I. Maevsky et al. A succinate-based composition reverses menopausal symptoms without sex hormone replacement therapy. Advances in gerontology= Uspekhi gerontologii/Rossiiskaia akademiia nauk, Gerontologicheskoe obshchestvo 21.2 (2008): 298-305.
2004
Scientific Research
A 3-year-long observational clinical study on 245 women was conducted. Enerlit-Clima (equivalent of Amberen’s formulation) was shown to be safe and effective when it came to managing several menopausal symptoms.
2015
Clinical Trial
Study design: A 12-week randomized, placebo-controlled, double-blind, study with 102 women between 42 and 60 years of age with mild to moderate menopause symptoms.
Results: Women who took Amberen showed statistically significant improvements compared to the placebo group. The results of the safety evaluation showed Amberen to be a safe dietary supplement.
Publications: I.V. Kuznetsova et al. Effectiveness of alternative therapy in perimenopausal and postmenopausal women (in Russian). Akusherstvo I ginekologiya/Obstetrics and Gynecology. 2016 5:126 - 33.
I.V. Kuznetsova et al. Effectiveness and safety of using a succinate-based dietary supplement for women in menopause. Medline.ru, 2016, Vol 17, Art. 3, p 24-45 (Mecine.ru/pdf)
Kuznetsova I.V, Uspenskaya Yu. B., Borisova N.I, Zhukova E.V., Berdnikova N.G., Gusak Yu. K Effectiveness and safety of using a succinate-based dietary supplement for women in menopause. Medline.ru, 2016, Vol 17, Art. 3, p 24-45 (Mecine.ru/pdf)
Presentations: Poster presentation at the 15th World Congress on Menopause. Effectiveness and safety of using Amberen supplementation in perimenopausal and postmenopausal women. Yu. Uspenskaya, I. Kuznetsova, N. Borisova, N. Berdnikova and U. Gusak
2016
Clinical Trial
Study design: A 12-week randomized, placebo-controlled, double-blind study with 125 women between 42 and 60 years of age with mild to moderate menopause symptoms.
Results: Amberen was shown to be a safe and well-tolerated supplement with no adverse side effects. Compared to the placebo group, women who took Amberen reported significant improvements in many menopausal symptoms.
Publications: V.E. Radzinskii et al. Treatment of climacteric symptoms with an ammonium succinate-based dietary supplement: a randomized, double-blind, placebo-controlled trial. (2016) Gynecological Endocrinology, 32:sup2, 64-68, DOI: 10.1080/09513590.2016.1232686
Presentations: Oral presentation of the 2015/2016 Amberen clinical trial results By Y.B. Uspenskaya: International Menopause Society, 25th World Congress on Controversies in Obstetrics, Gynecology and Infertility, Amsterdam, Netherlands, November 10-13, 2016.
2019
Research
Data from the 2016 and 2015 Amberen clinical trials involving a total of 227 women were pooled in order to continue to evaluate and further confirm Amberen’s efficacy.
V.E. Radzinsky et al. Succinate-Based Dietary Supplement for Menopausal Symptoms: A Pooled Analysis of Two Identical Randomized, Double-Blind, Placebo-Controlled Clinical Trials. Obstetrics and Gynecology International, vol. 2019, Article ID 1572196, 9 pages, 2019. https://doi.org/10.1155/2019/1572196.
2020
Scientific Research
Study Design: A 180-day (90-day intervention followed by 90-day observation) randomized, placebo-controlled, double-blind study with 105 women between 36 and 50 years of age with mild to moderate perimenopausal symptoms.
Results: Amberen Perimenopause was shown to be a safe and well-tolerated supplement with no adverse side effects. Compared to the placebo group, women who took Amberen reported significant improvements in many perimenopause symptoms. Perimenopausal women who participated in the clinical trial experienced menstrual regularity.^
Company
Customer Service
Legal
